Tay Therapeutics announces Publication of New Patent for Readthrough Agents Targeting Genetic Diseases

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Tay Therapeutics Secures £0.35 Million Innovate UK grant to investigate therapeutic applications of Readthrough compounds